Spanish flag Español
Medicina Interna Basada en la Evidencia

Portal para médicos

Síndromes coronarios agudos: avances 2020

09.08.2021
Ostre zespoły wieńcowe – postępy 2020
Przemysław Trzeciak (MD, PhD), Bartosz Hudzik (MD, PhD) Mariusz Gąsior (MD, PhD)

Nota: La revisión de las publicaciones abarca el período comprendido entre el 20/02/2020 y el 08/02/2021.

Siglas y abreviaturas: AAS — ácido acetilsalicílico, BNP (brain natriuretic peptide) — péptido natriurético tipo B, CK (creatine kinase) — creatina-cinasa, CK-MB (creatine kinase MB) — isoforma MB de la creatina-cinasa, COVID-19 (coronavirus disease) — enfermedad por coronavirus de 2019, cTn — troponina cardíaca, CV — cardiovascular, DAPT (dual antiplatelet therapy) — terapia antiplaquetaria dual, ESC — European Society of Cardiology, GP — glicoproteína plaquetaria, h-FABP (heart-type fatty acid binding protein) — proteína ligadora de ácidos grasos cardíacos, hs-cTn (high-sensitivity cardiac troponin) — prueba de troponina cardíaca alta sensibilidad, ICP — intervención coronaria percutánea, IMC — índice de masa corporal, IAMCEST — infarto agudo de miocardio con elevación del segmento ST, IAMSEST — infarto de miocardio sin elevación del segmento ST, MICAD (myocardial infarction with obstructive coronary artery disease) — infarto de miocardio con enfermedad coronaria obstructiva, MINOCA (myocardial infarction with non-obstructive coronary arteries) — infarto agudo de miocardio sin lesiones coronarias obstructivas, NT‑proBNP (N‑terminal pro-B-type natriuretic peptide) — fracción N-terminal del pro-péptido natriurético tipo B, PCR — proteína C-reactiva, SCA — síndrome coronario agudo, SCASEST — síndrome coronario agudo sin elevación del segmento ST, SLF — stent liberador de fármaco

Bibliografía:

 1. De Luca G., Verdoia M., Cercek M. y cols., Impact of COVID-19 pandemic on mechanical reperfusion for patients with STEMI, J. Am. Coll. Cardiol., 2020; 76: 2321-2330
2. Legutko J., Niewiara Ł., Bartuś S. y cols., Decline in the number of coronary angiography and percutaneous coronary intervention procedures in patients with acute myocardial infarction in Poland during the coronavirus disease 2019 pandemic, Kardiol. Pol., 2020; 78: 574-576
3. Choudry F.A., Hamshere S.M., Rathod S.M. y cols., High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction, J. Am. Coll. Cardiol., 2020; 76: 1168-1176
4. Collet J.P., Thiele H., Barbato E. y cols., 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC), Eur. Heart J., 2020; doi: 10.1093/eurheartj/ehaa575
5. Schüpke S., Neumann F.J., Menichelli M. y cols., ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes, N. Engl. J. Med., 2019; 381: 1524-1534
6. Piccolo R., Magnani G., Ariotti S. y cols., Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial, EuroIntervention, 2017; 13: 78-86
7. Chandrasekhar J., Baber U., Sartori S. y cols., Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study, Clin. Res. Cardiol., 2020; 109: 725-734
8. Gimbel M., Qaderdan K., Willemsen L. y cols., Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial, Lancet, 2020; 395: 1374-1381
9. Wallentin L., Becker R.C., Budaj A. y cols., Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N. Engl. J. Med., 2009; 361: 1045-1057
10. Ibanez B., James S., Agewall S. y cols., 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC), Eur. Heart J., 2018; 39: 119-177
11. Mehran R., Baber U., Sharma S.K. y cols., Ticagrelor with or without aspirin in high-risk patients after PCI, N. Engl. J. Med., 2019; 381: 2032-2042
12. Kim B.K., Hong S.J., Cho Y.H. y cols., Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome. The TICO randomized clinical trial, JAMA, 2020; 323: 2407-2416
13. Dreyer R.P., Tavella R., Curtis J.P. y cols., Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population, Eur. Heart J., 2020; 41: 870-878